CD39 Over-Expression Protects Against Ischemic-Induced AKI through Adenosine2- Receptor Mechanisms, but Promotes Renal Fibrosis

Rajakumar, S.; Roberts, Veena; Lü, Bo; Robson, Simon C.; d’Apice, Anthony J.F.; Cowan, Peter J.; Dwyer, Karen M.

doi:10.1097/00007890-201211271-02266

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…86,87 tolDC can also inhibit T-cell differentiation by preventing CD39 ectonucleotidase-mediated breakdown of extracellular ATP and subsequent activation of the proinflammatory purinergic P2X7-TLR-MyD88 signaling pathway. [88][89][90][91] Tissue macrophages are important sentinels of danger signals, including proinflammatory cytokines 92 and mediate an important role in allograft rejection. 93 Exposure of macrophages to IL-4 or IL-10 can polarize toward an M2 phenotype, [94][95][96][97][98] which is associated with anti-inflammatory characteristics and release of further IL-10 and TGF-β.…”

Section: Mechanisms Of Toldc-and Mreg-induced Tolerancementioning

confidence: 99%

See 1 more Smart Citation

Myeloid and Mesenchymal Stem Cell Therapies for Solid Organ Transplant Tolerance

Thomson

Rogers

2021

Transplantation

View full text Add to dashboard Cite

TRANSPLANT TOLERANCE AND TOLEROGENIC CELL TYPESImmunological tolerance is the "holy grail" of transplantation and describes nonreactivity of the recipient's immune system to the nonself, immunogenic donor Review Abstract. Transplantation is now performed globally as a routine procedure. However, the increased demand for donor organs and consequent expansion of donor criteria has created an imperative to maximize the quality of these gains. The goal is to balance preservation of allograft function against patient quality-of-life, despite exposure to long-term immunosuppression. Elimination of immunosuppressive therapy to avoid drug toxicity, with concurrent acceptance of the allograft-so-called operational tolerance-has proven elusive. The lack of recent advances in immunomodulatory drug development, together with advances in immunotherapy in oncology, has prompted interest in cell-based therapies to control the alloimmune response. Extensive experimental work in animals has characterized regulatory immune cell populations that can induce and maintain tolerance, demonstrating that their adoptive transfer can promote donor-specific tolerance. An extension of this large body of work has resulted in protocols for manufacture, as well as early-phase safety and feasibility trials for many regulatory cell types. Despite the excitement generated by early clinical trials in autoimmune diseases and organ transplantation, there is as yet no clinically validated, approved regulatory cell therapy for transplantation. In this review, we summarize recent advances in this field, with a focus on myeloid and mesenchymal cell therapies, including current understanding of the mechanisms of action of regulatory immune cells, and clinical trials in organ transplantation using these cells as therapeutics. (Transplantation 2021;105: e303-e321).

show abstract

Section: Mechanisms Of Toldc-and Mreg-induced Tolerancementioning

confidence: 99%

Section: Important Outcomes For Cell-based Therapies In Transplant To...mentioning

confidence: 99%

Myeloid and Mesenchymal Stem Cell Therapies for Solid Organ Transplant Tolerance

Thomson

Rogers

2021

Transplantation

View full text Add to dashboard Cite

show abstract

CD39 Over-Expression Protects Against Ischemic-Induced AKI through Adenosine2- Receptor Mechanisms, but Promotes Renal Fibrosis

Cited by 1 publication

References 0 publications

Myeloid and Mesenchymal Stem Cell Therapies for Solid Organ Transplant Tolerance

Myeloid and Mesenchymal Stem Cell Therapies for Solid Organ Transplant Tolerance

Contact Info

Product

Resources

About